Project update

Hepatitis C cure and ongoing challenges in post-cure lives

Australia is spending billions on the universal rollout of direct-acting antiviral drugs (DAAs) as part of its ambitious goal of achieving virtual elimination of hepatitis C by 2030. These ‘revolutionary’, ‘transformative’ drugs can bring about a sustained virological response – that is, a cure – for hepatitis C in over 90 percent of people treated. They are available on the Pharmaceutical Benefits Scheme for all Australians who are covered by Medicare.

Read More
Research

Hepatitis C from disability to cure – preliminary findings from ‘speculative legal mapping’

As Australia works towards its ambitious target of reducing hepatitis C stigma by 50% by 2022, it is necessary to investigate and understand the issues that continue to affect people who have – and have been treated for – hepatitis C. One significant example of such issues is the set of laws and policies devised in a pre-cure world that have yet to be reformed since the advent of curative treatments. Do people who had hepatitis C need to disclose this to insurers or prospective employers? And could you be refused employment or insurance on such a basis? Does the fact you once had hepatitis C need to be retained in your medical records? There are literally dozens of questions like these to be asked.

Read More
Announcement

Welcome to GLaD

We are delighted to introduce you to a new research program at the Australian Research Centre in Sex, Health and Society (ARCSHS).

Read More
New project

A world-first ‘post–human rights’ framework for drug policy

With new Australian drug laws required to comply with human rights frameworks, researchers at the GLaD program are conducting a new study funded by the Australian Research Countil to develop a world-first ‘post–human rights’ framework for drug policy.

Read More
New project

Social research project on hepatitis C and post-cure lives

In Australia, a new generation of direct-acting antivirals (DAAs) for the treatment of hepatitis C have been rolled out in a globally unique program of unrestricted, nationwide access. The new drugs, heralded as ‘revolutionary’, bring about a sustained virological response to hepatitis C in over 90 percent of people treated. By the end of 2019, […]

Read More
New article

Beyond a post-cure world

We are excited to announce the publication of the first article from the project, ‘Addressing hepatitis C-related legal, policy and practice discrimination in a post-cure world’.

Read More
Interview

An interview with GLaD research lead Kate Seear

Australia has long been a leader in critical alcohol and other drug (AOD) scholarship. Much of this work draws on feminist theory, including feminist science studies, to identify and examine ideas about agency and materiality in drug policy and practice. Often, this work also prioritises issues specific to gender, such as how the law conceptualises links between drugs and family violence, or how it understands the relationship between alcohol and sexual assault.

Read More